ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    Aducanumab AND Germany
Previous Study | Return to List | Next Study

221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (EMERGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02484547
Recruitment Status : Active, not recruiting
First Posted : June 29, 2015
Last Update Posted : August 6, 2018
Sponsor:
Information provided by (Responsible Party):
Biogen

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : January 30, 2020
  Estimated Study Completion Date : April 30, 2022